Christopher Hite, Executive Vice President and Chairman of Partnering at Royalty Pharma plc (RPRX), divested 117,592 shares of the company's stock on June 25, 2026. The transaction, executed at an average price of $54.47 per share, amounted to approximately $6.41 million.
This sale follows other recent insider transactions at Royalty Pharma, including sales by Marshall Urist and additional sales by Mr. Hite himself earlier in the week. Insider selling activities can occur for a variety of reasons, such as portfolio diversification or personal financial planning, and do not necessarily indicate a negative view of the company's future prospects.